Pfizer equity, debt and subsidiaries

Accuracy score :
97%

Summary (from the latest annual and quarterly report)

  • Total equity: 65 billion USD
  • Market Cap is 213 billion USD ( the last price of the stock is 38 USD)
  • Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets, Animal Health, and Consumer Healthcare
  • Total stockholders' equity has increased from 63 billion USD in 2019 to 65 billion in 2020
  • The company has 2.15 billion USD in cash on account
  • Total equity – cash on account = 65 billion USD – 2.15 billion USD = 62.85 billion USD
  • In Jun 2020 long-term debt was 36 billion USD, short – term debt was 16 billion USD. (In 2019 total debt was 53 billion USD)
  • The company's revenue has decreased in 2019 to 51.7 billion USD from 53.6 billion in 2018
  • Net income in 2019 was 16.2 billion USD, Net income in 2018 was 11.15 billion USD
  • In 2019 the company has paid 8 billion USD dividend to its shareholders

Opinion about the company

Fundamentally it is a good company and in the future, we can expect its growth (Total debt is 52 billion USD, the company has 2.15 billion USD in cash on account, ROE is around 20 %).

Pfizer is an American multinational pharmaceutical corporation headquartered in New York City. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. On December 19, 2018, Pfizer announced a joint merger of their consumer healthcare division with UK pharma giant GlaxoSmithKline; the British company will maintain a controlling share (listed at 68%). The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug. Pfizer is organised into nine principal operating divisions: Primary Care, Specialty Care, Oncology, Emerging Markets, Established Products, Consumer Healthcare, Nutrition, Animal Health, and Capsugel.

Acquisitions

  • Pfizer acquired Warner–Lambert in 2000 for 110 billion USD (Pfizer paid 90.3 billion USD in stock and rest in cash to acquire Warner-Lambert)
  • Pfizer merged with  Pharmacia in 2003 for 60 billion USD in stock (Pharmacia shareholders receive 1.4 shares of Pfizer stock for each share of Pharmacia)
  • Pfizer acquired in 2007 Coley Pharmaceutical for 164 million USD
  • Pfizer acquired in 2008 CovX for an undisclosed sum
  • Pfizer acquired in 2008 Encysive Pharmaceuticals  for 195 million USD
  • Pfizer acquired Wyeth  in 2009 for 68 billion USD. The deal cemented Pfizer's position as the largest pharmaceutical company in the world, with the merged company generating over US$20 billion in cash each year, and was the largest corporate merger since AT&T and BellSouth's US$70 billion deal in March 2006
  • In October 2010, Pfizer agreed to buy King Pharmaceuticals for 3.6 billion USD
  • Pfizer acquired in 2011 Icagen  for 60 million USD
  • Pfizer acquired in 2011 Excaliard Pharmaceuticals for 14 million USD
  • Pfizer acquired in 2012 Alacer for 360 million USD
  • Pfizer acquired in 2012 NextWave Pharmaceuticals  for 700 million USD
  • In 2014 Pfizer acquired Innopharma for 225 million USD, plus up to 135 million USD in milestone payments
  • Pfizer acquired Redvax  in 2015 for an undisclosed sum
  • In February 2015, Pfizer and Hospira agreed that Pfizer would acquire Hospira for 15.2 billion USD in cash
  • In May 2016, the company announced it would acquire Anacor Pharmaceuticals for 5.2 billion USD, expanding the companies portfolio in both inflammation and immunology drugs areas. On their final trading day, Anacor shares traded for $99.20 each, giving Anacor a market capitalization of 4.5 billion USD
  • In 2016 Pfizer acquired Bamboo Therapeutics for 645 million USD
  • Later, in August, the company announced the acquisition of cancer drug-maker - Medivation - for 14 billion USD
  • Two days later, Pfizer announced it would acquire AstraZeneca's small-molecule antibiotics business for 1.575 billion USD merging it into its Essential Medicines business
  • In May 2019 the company announced it would acquire Therachon for 810 million USD, expanding its rare disease portfolio through Theracons recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as achondroplasia. In June, Pfizer announced it would acquire Array Biopharma for 10.6 billion USD boosting its oncology pipeline

Total = 291.46 billion USD

  • In 2016, Pfizer Inc. was expected to merge with Allergan to create the Ireland-based "Pfizer plc" in a deal that would have been worth $160 billion. The merger was called off in April 2016, however, because of new rules from the United States Treasury against tax inversions, a method of avoiding taxes by merging with a foreign company.
  • In May 2020, Pfizer began testing four different coronavirus vaccine variations to help end the COVID-19 pandemic and planned to expand human trials to thousands of test patients by September 2020. The pharma giant, working alongside BioNTech (NASDAQ:BNTX), a German drugmaker with a North American base in Cambridge, Massachusetts, injected doses of its potential vaccine, BNT162, into the first human participants in the U.S. in early May. Based on the results, Pfizer said they "will be able to deliver millions of doses in the October time frame" and expects to produce hundreds of millions of doses in 2021
  • In July 2020, Pfizer and BioNTech announced that two of the partners' four mRNA vaccine candidates had won fast track designation from the FDA. The company began Phase 3 testing in the last week of July 2020 on 30,000 people and was slated to be paid $1.95 billion for 100 million doses of the vaccine by the United States. The U.S. deal priced two doses at $39 and the company stated that it would not lower the rates for other countries until the outbreak is no longer a pandemic. Pfizer's CEO stated the companies in the private sector producing a vaccine should make a profit

The Reports that you may like

Stock Title % of value Value per share 2020-09-30
(PFE) Pfizer Inc Pfizer equity, debt and subsidiaries 331.53 10.9100 2020-09-08
(GILD) Gilead Sciences Inc Gilead Sciences equity, debt and subsidiaries 134.39 46.2100 2020-09-08
(SHAK) Shake Shack Inc Shake Shack equity, debt and subsidiaries 145.62 2020-09-08
(INTC) Intel Corp Intel equity, debt and subsidiaries 192.44 26.6000 2020-09-08